RAD001 in Advanced Sarcoma

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

This trial intends to test the efficacy and safety of RAD001 in patients with advanced sarcoma who failed to conventional chemotherapy.

Phase 2

Asan Medical Center

Novartis

Everolimus
Sirolimus